FY2025 EPS Estimates for McKesson Boosted by Zacks Research

McKesson Co. (NYSE:MCKFree Report) – Analysts at Zacks Research boosted their FY2025 earnings estimates for McKesson in a research report issued to clients and investors on Tuesday, February 25th. Zacks Research analyst R. Department now expects that the company will earn $32.68 per share for the year, up from their previous forecast of $32.43. The consensus estimate for McKesson’s current full-year earnings is $32.77 per share. Zacks Research also issued estimates for McKesson’s Q4 2025 earnings at $9.70 EPS, Q1 2026 earnings at $8.16 EPS, Q2 2026 earnings at $8.49 EPS, Q4 2026 earnings at $9.52 EPS, FY2026 earnings at $35.73 EPS, Q1 2027 earnings at $8.10 EPS, Q3 2027 earnings at $11.90 EPS and FY2027 earnings at $41.06 EPS.

Other research analysts have also issued research reports about the stock. Evercore ISI boosted their target price on shares of McKesson from $650.00 to $675.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Bank of America cut their price objective on McKesson from $680.00 to $650.00 and set a “buy” rating for the company in a research report on Monday, January 6th. StockNews.com lowered McKesson from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. Morgan Stanley upped their price target on McKesson from $612.00 to $642.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Finally, Baird R W upgraded shares of McKesson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 7th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $645.79.

Check Out Our Latest Research Report on MCK

McKesson Trading Down 0.4 %

Shares of McKesson stock opened at $621.03 on Thursday. The firm has a fifty day simple moving average of $592.91 and a 200-day simple moving average of $563.46. The stock has a market capitalization of $77.83 billion, a price-to-earnings ratio of 28.44, a PEG ratio of 1.29 and a beta of 0.52. McKesson has a 1-year low of $464.42 and a 1-year high of $637.51.

McKesson (NYSE:MCKGet Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $8.03 EPS for the quarter, missing analysts’ consensus estimates of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%.

McKesson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Monday, March 3rd will be paid a $0.71 dividend. The ex-dividend date of this dividend is Monday, March 3rd. This represents a $2.84 dividend on an annualized basis and a yield of 0.46%. McKesson’s payout ratio is currently 13.00%.

Insider Buying and Selling

In other McKesson news, CEO Brian S. Tyler sold 8,961 shares of the company’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $597.99, for a total value of $5,358,588.39. Following the sale, the chief executive officer now directly owns 60,664 shares in the company, valued at $36,276,465.36. This represents a 12.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Leann B. Smith sold 579 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $602.81, for a total value of $349,026.99. Following the transaction, the executive vice president now owns 1,443 shares of the company’s stock, valued at $869,854.83. This represents a 28.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 19,268 shares of company stock valued at $11,536,378 over the last quarter. Corporate insiders own 0.11% of the company’s stock.

Hedge Funds Weigh In On McKesson

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital A Wealth Management LLC acquired a new position in shares of McKesson in the 4th quarter worth approximately $26,000. Millstone Evans Group LLC bought a new position in McKesson in the 4th quarter valued at $28,000. MidAtlantic Capital Management Inc. acquired a new position in McKesson in the third quarter worth $29,000. RPg Family Wealth Advisory LLC bought a new stake in shares of McKesson during the third quarter worth $31,000. Finally, Synergy Asset Management LLC acquired a new stake in shares of McKesson in the fourth quarter valued at $32,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.

About McKesson

(Get Free Report)

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

See Also

Earnings History and Estimates for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.